Results 61 to 70 of about 20,386 (204)

Fibrinogen Changes Before and After Intravenous Thrombolysis as Predictors of Cerebral Injury and Clinical Outcomes in Acute Ischemic Stroke: A Multicenter Prospective Cohort Study

Annals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 819-826, April 2026.
ABSTRACT Objective Plasma fibrinogen is essential in thrombosis and fibrinolysis, yet its dynamic changes pre‐ and post‐intravenous thrombolysis (IVT) for predicting brain injury severity and prognosis in acute ischemic stroke (AIS) patients remain unclear.
Wenhai Zhai, Yang Qu, Reziya Abuduxukuer, Kejia Zhang, Peng Zhang, Xin Tang, Huaimei Zhang, Lijuan Wang, Lichong Yang, Shuangxu Tan, Zhimei Yuan, Ce Han, Lili He, Yuping Zheng, Fenglan Zhao, Lijie Guo, Ligang Jiang, Jinfeng Li, Yongfei Jiang, Xuexia Zou, Dan Xu, Han Xu, Xiaojia Wang, Yingbin Qi, Xuefeng Hu, Yu Zhang, Zhen‐Ni Guo, Hang Jin, on behalf of the Biomarkers of Brain Injury Investigator Study Group   +28 more
wiley   +1 more source

Thrombolysis is associated with consistent functional improvement across baseline stroke severity: a comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA) [PDF]

, 2010
<p><b>Background and Purpose:</b> Baseline stroke severity predicts outcomes among thrombolysed patients. The baseline National Institutes of Health Stroke Scale (NIHSS) thresholds are sometimes used to select patients for thrombolysis,
Grotta, J.C., Lees, K.R., Lyden, P., Mishra, N.K.   +3 more
core   +1 more source

Changes in Immune‐Inflammation Status and Acute Ischemic Stroke Prognosis in Prospective Cohort

Annals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 767-779, April 2026.
ABSTRACT Background Inflammation is a critical risk factor for poor outcomes in cerebral infarction. Prior studies focused primarily on baseline inflammation status, neglecting dynamic longitudinal changes. We try to investigate the association between immune‐inflammation status alterations and stroke prognosis, and evaluated three systemic biomarkers'
Songfang Chen, Wenting Huang, Yitian Liu, Xuan Chen, Buyu Ke, Qian Shen, Hanyu Cai, Jing Sun, Yan Li, Yungang Cao, Beilei Hu, Keyang Chen   +11 more
wiley   +1 more source

Efficacy of argatroban plus alteplase according to time from onset to thrombolysis in acute ischemic stroke: a prespecified post-hoc analysis of the ARAIS trial

Frontiers in Neurology
BackgroundThe Argatroban Plus Recombinant Tissue-Type Plasminogen Activator for AIS (ARAIS) trial failed to demonstrate the benefit of argatroban in patients diagnosed with acute ischemic stroke who were treated with intravenous alteplase.
Yu Cui, Er-Qiang Wang, Yi-Han Wang, Hui-Sheng Chen   +3 more
doaj   +1 more source

Outcome of Treatment with Intravenous Alteplase in Acute Stroke Patients [PDF]

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2023
Background and Objective: Stroke is one of the main causes of death and disability in the world, and its treatment includes the re-supply of blood to the brain tissue using different methods, including alteplase injection.
H Nemati, P Saadat, A Ahmadi Ahangar, V Nematian, S Alijanpour, A Bijani   +5 more
doaj  

Association between time to reperfusion and outcome is primarily driven by the time from imaging to reperfusion [PDF]

, 2016
Background and Purpose A progressive decline in the odds of favorable outcome as time to reperfusion increases is well known. However, the impact of specific workflow intervals is not clear.; Methods We studied the mechanical thrombectomy group (n=103 ...
Cerda, Neus, Cobo Valeri, Erik, Dávalos Errando, Antoni, Jovin, Tudor G., Molina, Carlos A., Ribó, Marc, Sanroman, Luis, Tomasello, Alejandro, Urra, Xabier   +8 more
core   +2 more sources

Amyloid‐related imaging abnormalities (ARIA) in anti‐amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract In 2011, a workgroup of the Alzheimer's Association Research Roundtable introduced recommendations for detecting and monitoring amyloid‐related imaging abnormalities (ARIA) in Alzheimer's disease (AD) clinical trials. Since then, anti‐amyloid immunotherapies have received regulatory approval for AD treatment and are beginning to enter clinical
Ellis S. van Etten, Simin Mahinrad, Joshua D. Grill, Stephen Salloway, Alireza Atri, Petrice M. Cogswell, Tammie L. S. Benzinger, Takeshi Iwatsubo, Costantino Iadecola, Cynthia A. Lemere, James A. R. Nicoll, Steven M. Greenberg, Maria C. Carrillo, Clifford R. Jack Jr, Reisa A. Sperling   +14 more
wiley   +1 more source

Thrombolysis in very elderly people: controlled comparison of SITS international stroke thrombolysis registry and virtual international stroke trials archive [PDF]

, 2010
<p>Objective To assess effect of age on response to alteplase in acute ischaemic stroke.</p> <p>Design Adjusted controlled comparison of outcomes between non-randomised patients who did or did not undergo thrombolysis.
Ahmed, N., Andersen, G., Egido, J.A., Lees, K.R., Lindsberg, P.J., Mishra, N.K., Ringleb, P.A., Wahlgren, N.G.   +7 more
core   +1 more source

Assessment of Socio‐Demographic and Clinical Characteristics of Stroke Patients of a Tertiary Hospital in Bangladesh: A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Stroke is a major public health concern with significant socio‐economic implications. Understanding the sociodemographic and clinical characteristics of stroke patients is essential for effective prevention, management, and planning of healthcare services.
Sree Shib Shankar Devnath Debu, Ryadul Alam, Israt Jahan Eti, Dipak Kumar Mitra   +3 more
wiley   +1 more source

Evaluation of an Unfractioned Heparin Pharmacy Dosing Protocol for the Treatment of Venous Thromboembolism in Nonobese, Obese, and Severely Obese Patients [PDF]

, 2017
Background: Despite large interpatient variability in dose response, heparin is utilized for treatment of venous thromboembolism (VTE). Current data on the optimal heparin dosing in obese patients are conflicting. Objective: The objective was to evaluate
Breedlove, Emily Y., Hosch, Lindsey M., Knoderer, Chad A., Scono, Lauren E.   +3 more
core   +2 more sources